Search Results for "Skin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Skin. Results 111 to 120 of 123 total matches.

Treatment of Common Respiratory Tract Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
causes GI adverse effects and is associated with an increased risk of C. difficile infection. Skin rash ...
Most respiratory tract infections are caused by viruses. Bacterial respiratory tract infections are usually treated empirically with antibiotic therapy that targets the most probable causative pathogens. Recommended antibiotic regimens for outpatient treatment of some common respiratory tract infections are listed in Table 1 for adults and Table 2 for children.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):57-62   doi:10.58347/tml.2023.1674a |  Show IntroductionHide Introduction

Drugs for Bipolar Disorder

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024  (Issue 1699)
also cause hair loss, severe acne, and other skin reactions, and induce or exacerbate psoriasis ...
Bipolar disorder is characterized by episodes of mania, hypomania, and depression. Recurrences of manic or (more frequently) depressive symptoms are common. About 15-20% of patients with bipolar disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54   doi:10.58347/tml.2024.1699a |  Show IntroductionHide Introduction

Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
of the sulfonylurea chlorpropamide. It may increase the risk of skin rash in patients taking ampicillin ...
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75   doi:10.58347/tml.2023.1688a |  Show IntroductionHide Introduction

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
, serious skin reactions, interstitial lung disease HBV = hepatitis B virus; INF = interferon; PML ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
fungal infections, and other opportunistic infections. Tuberculin skin testing or interferon-gamma ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
, and skin. It can rarely cause myelotoxicity (generally with higher-thanrecommended doses or prolonged use ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Drugs for Cognitive Loss and Dementia

   
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022  (Issue 1657)
, muscle spasms, insomnia, abdominal pain, constipation, diarrhea, dizziness, abnormal dreams, and skin ...
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline is also associated with other neurological conditions such as Parkinson's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia.
Med Lett Drugs Ther. 2022 Aug 22;64(1657):129-36 |  Show IntroductionHide Introduction

Comparison Table: Some Lipid-Lowering Drugs (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
of peptic ulcers can occur ▶ Dry eyes and skin hyperpigmentation can occur rarely ▶ Flushing more common ...
View the Comparison Table: Some Lipid-Lowering Drugs
Med Lett Drugs Ther. 2022 Sep 19;64(1659):e152-6 |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
pain, pulmonary toxicity, hepatotoxicity, optic neuritis, corneal microdeposits, skin discoloration ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
skin reactions, including exfoliative dermatitis, The Medical Letter ® Vol. 64 (1645) March 7, 2022 ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction